Cancer Letters
Volume 228, Issue 1 , Pages 83-90 , 18 October 2005

Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era

  • Yael P. Mosse

      Affiliations

    • Division of Oncology, Children's Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Blvd, Philadelphia, PA 19104-4318, USA
    • Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • ,
  • Joel Greshock

      Affiliations

    • Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • ,
  • Barbara L. Weber

      Affiliations

    • Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • ,
  • John M. Maris

      Affiliations

    • Division of Oncology, Children's Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Blvd, Philadelphia, PA 19104-4318, USA
    • Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • Corresponding Author InformationCorresponding author. Address: Division of Oncology, Children's Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Blvd, Philadelphia, PA 19104-4318, USA. Tel.: +1 215 590 2821; fax: +1 215 590 3770.

Received 7 January 2005 ,Accepted 5 February 2005.

References 

  1. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J. Clin. Oncol. 1999;17:2264–2279
  2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer. 2003;3:203–216
  3. Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, et al. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res. 2004;14:287–295
  4. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics. 2004;20:1233–1240
  5. Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat. Genet. 2001;29:459–464
  6. Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Eynstein Lonning P, Kaaresen R, et al. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc. Natl Acad. Sci. USA. 2001;98:7952–7957
  7. Albertson DG, Pinkel D. Genomic microarrays in human genetic disease and cancer. Hum. Mol. Genet. 2003;12:R145–R152
  8. Greshock J, Naylor TL, Margolin A, Diskin S, Cleaver SH, Futreal PA, et al. 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res. 2004;14:179–187
  9. Van Roy N, Jauch A, Van Gele M, Laureys G, Versteeg R, De Paepe A, et al. Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines. Cancer Genet. Cytogenet. 1997;97:135–142
  10. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, et al. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res. 2001;61:679–686
  11. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression, but not decreased overall survival probability, in neuroblastoma patients: a Children's Cancer Group Study. J. Clin. Oncol. 2000;18:1888–1899
  12. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18:4948–4957
  13. De Preter K, Speleman F, Combaret V, Lunec J, Laureys G, Eussen BH, et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod. Pathol. 2002;15:159–166
  14. Morowitz M, Shusterman S, Mosse Y, Hii G, Winter CL, Khazi D, et al. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. Mod. Pathol. 2003;16:1248–1256
  15. Mathew P, Valentine MB, Bowman LC, Rowe ST, Nash MB, Valentine VA, et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia. 2001;3:105–109
  16. Takita J, Hayashi Y, Takei K, Yamaguchi N, Hanada R, Yamamoto K, et al. Allelic imbalance on chromosome 18 in neuroblastoma. Eur. J. Cancer. 2000;36:508–513
  17. Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Boecker W, Lampert F, et al. Comparative genomic hybridization (CGH) analysis of neuroblastomas-an important methodological approach in paediatric tumour pathology. J. Pathol. 1997;181:394–400
  18. Van Gele M, Van Roy N, Jauch A, Laureys G, Benoit Y, Schelfhout V, et al. Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis. Eur. J. Cancer. 1997;33:1979–1982
  19. Vandesompele J, Van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P, et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer. 1998;23:141–152
  20. Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int. J. Cancer. 2001;91:680–686
  21. lehara T, Hamazaki M, Sawada T. Cytogenetic analysis of infantile neuroblastomas by comparative genomic hybridization. Cancer Lett. 2002;178:83–89
  22. Schleiermacher G, Janoueix-Lerosey I, Combaret V, Derre J, Couturier J, Aurias A, et al. Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet. Cytogenet. 2003;141:32–42
  23. Beheshti B, Braude I, Marrano P, Thorner P, Zielenska M, Squire JA. Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia. 2003;5:53–62
  24. Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, et al. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics. 2004;5:70
  25. Hallstensson K, Thulin S, Aburatani H, Hippo Y, Martinsson T. Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma. Eur. J. Cancer. 1997;33:1966–1970
  26. Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T, et al. Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene. 2000;19:4302–4307
  27. Martinsson T, Sjoberg RM, Hedborg F, Kogner P. Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma. Cancer Genet. Cytogenet. 1997;95:183–189
  28. Origone P, Defferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B, Tonini GP. Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am. J. Med. Genet. 2003;118:309–313
  29. Ejeskar K, Aburatani H, Abrahamsson J, Kogner P, Martinsson T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br. J. Cancer. 1998;77:1787–1791
  30. Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, et al. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?. Med. Pediatr. Oncol. 2001;36:5–10
  31. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin. Cancer Res. 2003;9:52–58
  32. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med. 1995;1:249–255
  33. Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schafer KL, Terpe HJ, et al. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br. J. Cancer. 1998;77:2223–2229

PII: S0304-3835(05)00363-0

doi: 10.1016/j.canlet.2005.02.052

Cancer Letters
Volume 228, Issue 1 , Pages 83-90 , 18 October 2005

Article Tools

* Image Usage & Resolution